Off-label use of new oral anticoagulants: a one-way ticket to nowhere
Related Experiment Video
Updated: Apr 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Carlos A Molina1, Magdy H Selim1
1From the Stroke Unit, Department of Neurology, Hospital Vall d'Hebron-Barcelona, Barcelona, Spain (C.A.M.); and Stroke Division, Beth Israel Deaconess Medical Center, Boston, MA (M.H.S.). cmolina@vhebron.net mselim@bidmc.harvard.edu.
No abstract available in PubMed .
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

